Get the Stockscreener App
214.95
0.36%
0.77
After Hours:
214.95
Overview
News
Price History
Option Chain
Financials
Discussions
Forecast
Stock Split
Dividend History
Cardinal Health Inc stock is traded at $214.95, with a volume of 1.41M.
It is up +0.36% in the last 24 hours and down -0.98% over the past month.
Cardinal Health is one of three leading pharmaceutical wholesalers in the US, engaged in sourcing and distributing of branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail order), hospital networks, and healthcare providers. Cardinal, Cencora, and McKesson hold well over 90% of the US pharmaceutical wholesale industry. Cardinal Health also supplies medical-surgical products and equipment to healthcare facilities in North America, Europe, and Asia.
See More
Previous Close:
$214.18
Open:
$213.02
24h Volume:
1.41M
Relative Volume:
0.83
Market Cap:
$50.58B
Revenue:
$244.67B
Net Income/Loss:
$1.68B
P/E Ratio:
30.93
EPS:
6.9487
Net Cash Flow:
$5.51B
1W Performance:
+1.02%
1M Performance:
-0.98%
6M Performance:
+39.41%
1Y Performance:
+59.48%
1-Day Range:
$212.70
$216.46
1-Week Range:
$211.66
$217.77
52-Week Range:
$129.52
$233.60
Cardinal Health Inc Stock (CAH) Company Profile
Name
Cardinal Health Inc
Sector
Industry
Phone
(614) 757-3033
Address
7000 CARDINAL PLACE, DUBLIN, OH
Compare CAH vs MCK, COR, HSIC, AHG
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CAH
Cardinal Health Inc
|
214.95 | 50.72B | 244.67B | 1.68B | 5.51B | 6.9487 |
MCK
Mckesson Corporation
|
862.79 | 106.03B | 397.96B | 4.55B | 9.64B | 34.77 |
COR
Cencora Inc
|
319.90 | 62.41B | 325.78B | 1.64B | 3.61B | 8.3139 |
HSIC
Henry Schein Inc
|
77.20 | 8.65B | 13.18B | 419.00M | 521.00M | 3.2704 |
AHG
Akso Health Group Adr
|
2.36 | 1.96B | 14.85M | -136.07M | 7.25M | -0.4726 |
Cardinal Health Inc Stock (CAH) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-09-26 | Upgrade | Citigroup | Neutral → Buy |
| Dec-09-25 | Initiated | Barclays | Overweight |
| Jun-03-25 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Feb-05-25 | Upgrade | Jefferies | Hold → Buy |
| Jan-08-25 | Upgrade | TD Cowen | Hold → Buy |
| Jan-07-25 | Upgrade | Evercore ISI | In-line → Outperform |
| Jan-06-25 | Upgrade | BofA Securities | Neutral → Buy |
| Dec-13-24 | Upgrade | Wells Fargo | Underweight → Equal Weight |
| Dec-04-24 | Resumed | Mizuho | Outperform |
| Feb-26-24 | Initiated | Leerink Partners | Outperform |
| Feb-09-24 | Upgrade | Argus | Hold → Buy |
| Jan-03-24 | Initiated | Barclays | Overweight |
| Dec-14-23 | Initiated | Wells Fargo | Underweight |
| Jul-10-23 | Downgrade | Evercore ISI | Outperform → In-line |
| Mar-31-23 | Initiated | Citigroup | Neutral |
| Feb-03-23 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Nov-04-22 | Upgrade | BofA Securities | Underperform → Neutral |
| Aug-22-22 | Resumed | Morgan Stanley | Overweight |
| May-26-22 | Downgrade | Barclays | Overweight → Equal Weight |
| May-18-22 | Upgrade | Evercore ISI | In-line → Outperform |
| Apr-12-22 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Apr-01-22 | Resumed | Credit Suisse | Neutral |
| Aug-06-21 | Downgrade | Deutsche Bank | Buy → Hold |
| Aug-05-21 | Downgrade | BofA Securities | Buy → Underperform |
| May-10-21 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Jan-08-21 | Upgrade | Wolfe Research | Underperform → Peer Perform |
| Nov-02-20 | Upgrade | Barclays | Equal Weight → Overweight |
| Sep-25-20 | Upgrade | Deutsche Bank | Hold → Buy |
| Jul-20-20 | Upgrade | Guggenheim | Neutral → Buy |
| May-15-20 | Upgrade | UBS | Neutral → Buy |
| Apr-23-20 | Resumed | Credit Suisse | Neutral |
| Mar-20-20 | Upgrade | BofA/Merrill | Underperform → Buy |
| Feb-12-20 | Upgrade | Morgan Stanley | Underweight → Equal-Weight |
| Feb-07-20 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Dec-16-19 | Downgrade | Guggenheim | Buy → Neutral |
| Sep-12-19 | Initiated | Deutsche Bank | Hold |
| Aug-27-19 | Downgrade | Argus | Buy → Hold |
| Aug-20-19 | Upgrade | Guggenheim | Neutral → Buy |
| Apr-18-19 | Initiated | Guggenheim | Neutral |
| Jan-17-19 | Initiated | UBS | Neutral |
| Nov-16-18 | Downgrade | Leerink Partners | Outperform → Mkt Perform |
| Apr-24-18 | Upgrade | Leerink Partners | Mkt Perform → Outperform |
| Apr-02-18 | Upgrade | Argus | Hold → Buy |
| Mar-08-18 | Initiated | Barclays | Equal Weight |
| Feb-27-18 | Resumed | BofA/Merrill | Underperform |
| Jan-05-18 | Initiated | Evercore ISI | In-line |
View All
Cardinal Health Inc Stock (CAH) Latest News
Cardinal Health Report: Expanding Advanced Therapies into Community Care - Intellectia AI
More advanced treatments are moving beyond hospitals and closer to home - Stock Titan
Evercore ISI Trims Cardinal Health (CAH) Target While Maintaining Bullish Rating - Yahoo Finance
Walton Hills warehouse used by Cardinal Health fetches nearly $40 million - Crain's Cleveland Business
Here's why you should add Cardinal Health stock to your portfolio now - MSN
Robeco Institutional Asset Management Trims Cardinal Health Holdings - National Today
Burney Co. Boosts Cardinal Health Stock Position by 27% - National Today
Cardinal Health Reports Third Quarter Fiscal Year 2025 Results and Raises Fiscal Year 2025 Outlook - ADVFN
Cardinal Health Stock (CAH) Opinions on Geopolitical Sell-Off and Leadership Shift - Quiver Quantitative
Cardinal Health Tops Volume Charts With $280 Million Trade As Specialty Boom Drives Investor Reassessment - Bitget
How The Cardinal Health (CAH) Investment Story Is Shifting As Analysts Rework Their Models - Yahoo Finance
Expanded Actinium‑225 Capacity And Higher EPS Guidance Could Be A Game Changer For Cardinal Health (CAH) - Yahoo Finance
Charles River Labs stock: Margin Boost from Divestitures Signals Buy Opportunity - AD HOC NEWS
Charles River Labs stock: New Asia partnership signals growth potential - AD HOC NEWS
Robotic Pharmacy Prescription Market Research and Global Forecast Report 2025-2032 - GlobeNewswire Inc.
How Investors Are Reacting To Cardinal Health (CAH) Expanding Actinium-225 Capacity For Targeted Alpha Therapies - Sahm
Here’s Why Investing in Cardinal Health Shares Could Benefit Your Portfolio Right Now - Bitget
Cardinal Health (CAH) Gains But Lags Market: What You Should Know - Yahoo Finance Singapore
Cardinal Health Inc. stock rises Wednesday, still underperforms market - MarketWatch
CAH PE Ratio & Valuation, Is CAH Overvalued - Intellectia AI
Here's Why You Should Add Cardinal Health Stock to Your Portfolio Now - TradingView — Track All Markets
Evercore Maintains Cardinal Health(CAH.US) With Buy Rating, Cuts Target Price to $240 - Moomoo
Cardinal Health Faces "Beat and Raise" Test as Raised Guidance Becomes New Baseline - Bitget
Is Cardinal Health (CAH) Stock Undervalued Right Now? - Yahoo Finance
A Look At Cardinal Health (CAH) Valuation After Expanded Actinium-225 Cancer Therapy Production - Sahm
Cardinal Health, Inc. (CAH) stock price, news, quote and history - Yahoo Finance UK
Longtime supervisor sues Cardinal Health over age and gender bias - hcamag.com
Cardinal Health, Inc. (CAH) Stock Price, News, Quote & History - Yahoo! Finance Canada
Cardinal Health ER Laceration Tray ACS-SLAC1 | Health Supply 770 INC - primetimes.id
Assessing Cardinal Health (CAH) Valuation After Its Recent Share Price Move - Yahoo Finance
Cardinal Health (NYSE:CAH) Upgraded at Wall Street Zen - MarketBeat
Global Clinical Drainage Supplies Market Dominated by North America as Cardinal Health and Medline Expand Products - Carroll County Mirror-Democrat
Wells Fargo raises outlook on Cardinal Health (CAH), cites broad business strength - MSN
Tema Etfs LLC Trims Cardinal Health Stock Position - National Today
Tema Etfs LLC Decreases Stock Position in Cardinal Health, Inc. $CAH - MarketBeat
9 Best-Performing Health Care Stocks for April 2026 - NerdWallet
Cardinal Health Inc (CLH.SG) stock price, news, quote and history - Yahoo Finance UK
Cardinal Health Increases Ac-225 Production to Enhance Cancer Treatment Options - Bitget
Cardinal Health Expands Ac-225 Capacity to Boost Cancer Therapies - Yahoo Finance
HF Advisory Group LLC Buys 5,049 Shares of Cardinal Health, Inc. $CAH - MarketBeat
Kwmg LLC Has $16.51 Million Position in Cardinal Health, Inc. $CAH - MarketBeat
Cardinal Health Deepens Actinium-225 Role As Board Leadership Shifts - Yahoo Finance
Cardinal Health, Shine Technologies amp up domestic production of radiopharmaceuticals - Healthcare Brew
Cardinal Health (CAH) Boosts Actinium-225 Production for Future Therapies - GuruFocus
Can CAH's Specialty Flywheel Strategy Unlock Long-Term Growth? - The Globe and Mail
Cardinal Health (CAH) Boosts Actinium-225 Production Capacity - GuruFocus
Insiders At Cardinal Health Sold US$53m In Stock, Alluding To Potential Weakness - Yahoo Finance
Nisa Investment Advisors LLC Trims Stock Position in Cardinal Health, Inc. $CAH - MarketBeat
Cardinal Health expands Actinium-225 production capacity to support growing demand for novel cancer therapies - PR Newswire
List of 30 Acquisitions by Cardinal Health (Apr 2026) - Tracxn
Can CAH’s Unique Specialty Flywheel Approach Drive Sustainable Growth Over Time? - Bitget
Cardinal Health Inc Stock (CAH) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.24%
3.67%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):